1. Death to Cleanrooms in Biopharmaceutical Manufacturing

    Marc Pelletier, Ph.D., Director of CRB USA explains the benefits of closed processing.

  2. Fully Supporting Customer Needs for Biologics Development and Manufacturing

    James Park, Senior Vice President and Global Head, Business Development Center for Samsung BioLogics discusses the construction of three state-of-the-art production facilities in the last seven years.

  3. Meeting the Need for Small-Volume API Manufacturing

    Jim Scandura, Executive VP, Chief Operating Officer; Gary Butler, Vice President & Avlon Site Director; and Werner Kunz, Vice President & Shannon Site Director at Avara Pharmaceutical Services explain the integrated API service offering.  

  4. Focused on Fermentation

    Capua BioServices continues to invest to support modern fermentation, explains Elise Mous Director Sales & Marketing/Business Development and Thomas De Maria, Business Development Manager.

  5. Leveraging Lyophilization Development Expertise for Clinical Manufacturing

    By late 2018, AB BioTechnologies, Inc.will be providing cGMP manufacturing of Phase I-III clinical trial material and small-volume commercial products, says Jeff Schwegman, Founder & CEO.

  6. Meet Chemo CMO: Preferred Partner for Injectables Manufacturing
    Masha Kononov, Sr. Commercial Manager at Chemo discusses a recent capacity expansion.
  7. MSD Launches Herceptin Biosimilar in UK
    Ontruzant (trastzumab) is the first biosimilar in Europe to Roche’s Herceptin. 
  8. WeHealth by Servier and DEEPLINK MEDICAL sign a partnership to develop a new e-health solution

    eHealth by Servier, the Servier Group’s e-Health department, and DEEPLINK MEDICAL signed a partnership to develop an e-Health solution designed to improve the monitoring of patients with solid tumors.

  9. Siegfried Purchases the Drug Product Manufacturing Facility of Arena Pharmaceuticals GmbH in Zofingen

    The Siegfried Group has acquired of the drug product manufacturing facility, with all related employees and contracts, from Arena Pharmaceuticals GmbH in Zofingen, Switzerland. 

  10. FDA Accepts for Filing Supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) in Adult Patients with Sialorrhea

    Merz North America announced that the FDA has accepted for filing a supplemental Biologics License Application (sBLA) for Xeomin® (incobotulinumtoxinA) for the treatment of chronic sialorrhea due to Parkinson’s Disease or other neurologic disorders in adult patients.

  11. Investing in New Technologies for Innovative Functional Solutions

    Sarath Chandar, Chief Scientific Officer, Applied Innovation Group at SPI Pharma discusses the how the company is re-engaging in innovation.

  12. Supporting Parenteral Development and Manufacturing with End-to-End Services

    Oskar Gold, Senior Vice President of Key Account Management and Marketing/Corporate Communications for Vetter explains leveraging end-to-end support.

  13. Microbial and Biological Decontamination of Equipment Brings Peace of Mind

    Matt Hicks, Chief Operating Officer & Counsel for Federal Equipment Company explains how used equipment presents no risk of cross contamination.

  14. A New Landscape: M&A in the Discovery & Research Sector

    The CRO market is condensing while experiencing rapid growth.

  15. What’s Driving M&A Among Pharma Sponsors?

    Merger and acquisition activity is, overall, driven by a need to improve competitiveness.

  16. Getting to the Finish Line

    The industry’s accelerating development of biopharmaceuticals has put tremendous pressure on the entire supply chain to improve and modernize fill/finish operations.

  17. WuXi Biologics to Supply Antibody Drugs for Adagene, Inc.
    Strategic collaboration focused on the supply of clinical trial materials for IND’s filed in China and the US.
  18. European Commission Expands Marketing Approval for GSK’s Relvar Ellipta

    The inhaled corticosteroid (ICS) / long-acting β2-agonist (LABA) combination is now approved for more patients with asthma.

  19. Abzena Strengthens Specialized Bioassay Offering Through Access Agreement with Major Cell Line Depository

    The agreement with an unnamed institution will allow Abzena access to cell lines representing multiple different species, tissue types and genetic disorders.

  20. FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) for Treatment of Advanced Cervical Cancer

    This is the first filing acceptance and Priority Review granted for an anti-PD-1 therapy in cervical cancer and the 14th regulatory submission accepted by the FDA for KEYTRUDA.

Nice Insight Awareness/Perception Scorecard

Research. Compare. Contact. Find the Ideal Partner.

Customer Awareness (CA) describes a buyer’s knowledge of your offering, while Customer Perception (CP) describes how a buyer rates your company based on that knowledge. Nice Insight’s CA/CP scorecard allows you to measure market awareness and perception of you and your industry peers based on acknowledged outsourcing drivers.

  1. Search by company type, region, market segment and services.
  2. Select up to 5 companies to compare.
  3. View CA & CP performance scores against industry benchmark ratings.

MSD Launches Herceptin Biosimilar in UK

Mar 16, 2018 2:35:46 PM PAO-M03-18-NI-015
Strategic Collaboration

WuXi Biologics to Supply Antibody Drugs for Adagene, Inc.

Mar 15, 2018 2:54:10 PM PAO-M03-18-NI-014

European Commission Expands Marketing Approval for GSK’s Relvar Ellipta

Mar 15, 2018 2:51:24 PM PAO-M03-18-NI-013
Cell and Gene Therapy

Oxford BioMedica is Making Big Moves

Mar 13, 2018 11:28:35 AM PAO-M03-18-NI-012

Colorcon Up and Running in Puerto Rico

Mar 13, 2018 11:21:58 AM PAO-M03-18-NI-011

New BI Vaccine Allows Very Early Vaccination of Piglets Against Swine Flu

Mar 9, 2018 12:29:29 PM PAO-M03-18-NI-010

DSM Sinochem Pharmaceuticals Is for Sale

Mar 9, 2018 12:26:45 PM PAO-M03-18-NI-009

Lilly Reports Results of Migraine Survey

Mar 9, 2018 12:19:50 PM PAO-M03-18-NI-007

Nice Insight Overview

M&A Activity in a Fragmented CDMO Market
While there has been a slowdown in M&A in the pharmaceutical industry, the contract services market remains highly fragmented and players large and small continue to enhance their competitiveness through inorganic growth.


M&A: What Role has M&A Played in your Company’s Growth?

In Conversation

Operational Excellence in Outsourced Fill-Finish Services
Nice Insight is in conversation with Oskar Gold at Vetter Pharma International, a global leader in the fill-finish of aseptically prefilled syringe systems, cartridges and vials, about how outsourced supply of such services can help companies of all sizes.

In Conversation

M&A: Combining Market Segments

Dago Caceres and Gary Lord, The Dow Chemical Company